US › Healthcare

Tvardi Therapeutics, Inc. (TVRD)

US · Healthcare · Biotechnology

$2.03+0.50%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-6.8M
Profit YoY
-38.7%
EPS
$-0.73
EPS estimate
$-0.65

EPS came in at -0.73 against a street estimate of -0.65 — a miss of 12.3%.

Key statistics

Market cap
$19.0M
Forward P/E
0.0
P/B
1.36
Book value
$1.55
EPS (TTM)
$-0.27
52-week high
$43.65
52-week low
$1.50
50-day MA
$2.82
200-day MA
$3.71

Analyst view

Analysts rate Tvardi Therapeutics, Inc. a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $8.50.

Shareholding

Insiders
26.02%
Institutions
22.31%

Largest institutional holders

FundStake
Slate Path Capital LP7.51%
BlackRock Inc4.14%
Vanguard Capital Management, LLC3.67%
American Financial Group Inc2.38%
Geode Capital Management, LLC1.94%
Silvercrest Asset Management Group LLC1.08%
State Street Corp1.04%
Renaissance Technologies Corp0.98%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tvardi Therapeutics, Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.